NeuroSense Therapeutics | Investor Presentation Deck

Slide schematic 4/4

image 1/1 list 2/2 title 1/1

Components 4

logo bullet bullet headline

Tools 1

list/bullet: Inclusion Criteria: Males or females 18-75, ALS diagnosis, <30 months duration, ALSFRS-R slope >= 0.3, ALSFRS-R >= 25, Swallowing >= 3, concurrent Riluzole/Edaravone/TUDCA allowed, SVC >= 60%, 18 < BMI < 30

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · slide 14